SCHEMBL2807111

SCHEMBL2807111

O=S(=O)(NC1CCc2c(cnc3[nH]ncc23)C1)c1ccc(F)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
RB1 P06400 1/20 0.40
HDAC8 Q9BY41 4/20 0.40
PNMT P11086 1/20 0.39
HTR7 P34969 4/20 0.38
HTR1A P08908 3/20 0.38
DRD2 P14416 2/20 0.38
HTR6 P50406 2/20 0.38
TBXA2R P21731 2/20 0.37
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 2/20 0.36
HTT P42858 2/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805699 0.89 RB1 (0.52) RB1HDAC8HTR7HTR1ADRD2
SCHEMBL2806632 0.87 HDAC8 (0.50) RB1HDAC8PNMTHTR7HTR1A
SCHEMBL2803941 0.87 ALDH1A1 (0.49) TDP1RB1HDAC8PNMTTBXA2R
SCHEMBL2808103 0.86 HDAC8 (0.49) KMT2ARB1HDAC8PNMTTBXA2R
SCHEMBL2804144 0.85 TBXA2R (0.42) HDAC8DRD2HTR6TBXA2RALDH1A1
SCHEMBL2804752 0.85 HDAC8 (0.50) HDAC8HTR7HTR1ADRD2HTR6
SCHEMBL2803517 0.85 RB1 (0.40) KMT2ARB1HDAC8PNMTTBXA2R
SCHEMBL2804951 0.85 ALDH1A1 (0.44) RB1TBXA2RALDH1A1HTTTSHR
SCHEMBL2805284 0.84 SGK1 (0.46)
SCHEMBL2489862 0.84 RB1 (0.43) RB1HDAC8PNMTHTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 KMT2A 1795/4885TDP1 1860/4885RB1 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.